Thus, these CAR-T cell therapies have been approved for treating patients with CD19-positive B cell malignancies among non-Hodgkin’s lymphoma, such as r/r DLBCL, B-ALL, and mantle cell lymphoma [7,8]. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.